International Journal of Pharma and Bio Sciences
ijpbs.net
editorijpbs@rediffmail.com (or) editorofijpbs@yahoo.com (or) prasmol@rediffmail.com
10.22376/ijpbs.2019.10.1.p1-12
Volume 14 Issue 1
January - March
A Review On Nanostructure Drug Carriers for Treatment and Management of Neuroendocrine Cancer
Neuroendocrine (NE) cancer is a tumour that develops from neuroendocrine cells, which release hormones into the bloodstream and regulate body function. Neuroendocrine cancer can alter the normal function of neuroendocrine cells. Conventional therapies have limitations for treating Neuroendocrine cancer cells which arise the need for specific nanocarriers that can target and enable the drug release in a sustainable and controllable manner. Nanocarriers like dendrimers, carbon nanotubes, liposomes, gold nanoparticles, solid lipid nanoparticles, quantum dots, polymer nanoparticles, magnetic nanoparticles, and hybrid nanoparticles have spatial and temporal delivery ability. Nanomaterial used in nanocarriers plays a vital role in the release rate of the drug, specific targeting, diagnostic purpose, and prolongation time. Besides, the specific targeting potential of nanocarriers leads to diminished side effects. Additionally, surface-modified nanomaterials may offer better antitumour effects in neuroendocrine cancer therapy. Hence, nanocarriers can be effectively employed for the management of neuroendocrine cancer with specific targeting and minimal side effects compared to conventional therapy. Recently, there has been a lot of concern about the creation of cancer nanotherapeutics. Cancer nanotherapeutics have circumvented a number of the drawbacks of conventional medicines, including poor water solubility, nonspecific biodistribution, and restricted bioavailability. The main building blocks of nanotherapeutics are nanoparticles with tailored size and surface properties that are intended to either passively or actively transport anti-cancer medications to tumour cells. The present study overviews current developments in cancer therapeutics based on tumour-targeting delivery methodologies and nanoparticle drug delivery systems.
Avhipsha Kar, Dr. Gaurav Agarwal and Dr. Shilpi Agarwal
Neuroendocrine Cancer, Nanomaterials, Gold Nanoparticles, Dendrimers, Liposomes.Tumour Targeting, Cancer Treatment, Nanoparticles.
1-9